Raymond James Financial’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Raymond James Financial’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Sell	5,497 -33	-0.6%	-$1.93K	﹤0.01%	4713
2026 Q1	$299K	Sell	5,530 -9,082	-62%	-$506K	﹤0.01%	4656
2025 Q4	$818K	Sell	14,612 -1,721	-11%	-$89.2K	﹤0.01%	3914
2025 Q3	$783K	Buy	16,333 +3,405	+26%	+$152K	﹤0.01%	3841
2025 Q2	$525K	Sell	12,928 -9,420	-42%	-$379K	﹤0.01%	3981
2025 Q1	$979K	Buy	22,348 +4,623	+26%	+$204K	﹤0.01%	3510
2024 Q4	$762K	Buy	+17,725	New	+$806K	﹤0.01%	3640

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Raymond James Financial's XPH Position: Q2 2026 in Review

Raymond James Financial reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 0.6% in Q2 2026, selling an estimated $1.93K and leaving 5,497 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #4713.

Raymond James Financial first reported a position in XPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $979K in Q1 2025. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

Raymond James Financial held 5,497 shares of State Street SPDR S&P Pharmaceuticals ETF worth $364K as of Q2 2026.
Raymond James Financial sold 33 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $1.93K.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4713 holding.
Raymond James Financial first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's State Street SPDR S&P Pharmaceuticals ETF position peaked at $979K in Q1 2025.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.